EVALUATION OF THE QUALITY OF LIFE AND GASTROINTESTINAL SYMPTOMS AFTER CONVERSION TO MYFORTIC (ERL080) and CELLCEPT WITHDRAWAL IN MAINTENANCE RENAL TRANSPLANT RECIPIENTS TREATED WITH TACROLIMUS.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2004-000782-35-IT

Enrollment

100

Registered

2005-11-11

Start date

2004-06-10

Completion date

Unknown

Last updated

2012-03-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prophylaxis of transplant rejection in adult patients receiving calcineurin inhibitors with / without corticosteroids after allogeneic renal transplants. MedDRA version: 6.1 Level: PT Classification code 10023439

Interventions

Product Name: MYCOPHENOLIC ACID Product Code: ERL080 Pharmaceutical Form: Gastro-resistant tablet INN or Proposed INN: Mycophenolic acid Concentration unit: mg milligram(s) Concentration type: equal C

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Main Objective: ;Secondary Objective: ;Primary end point(s):	—

Countries

Italy

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026